🎵There are some minor side effects, and some are not that rare
Like nausea, vomiting, and losing all your hair
And heart attacks, becoming gay, and growing extra breasts
But it's fucking cheap and hey, this is the NHS

Paracetamoxyfrusebendroneomycin
Paracetamoxyfrusebendroneomycin🎵

Compiled by the Endocrine Metabolic Research Unit, Leeds Teaching Hospital NHS Trust

In Association with Her Majesty’s Revenue and Customs, and the Treasury

The Fauzempic (FMZ-01) government-funded trial was launched to evaluate the safety and efficacy of a GLP-1 analogue formulated as a weight-reduction therapy designed to enhance cardiometabolic health through selective adipose redistribution. FMZ-01 triggers the relocation of high-risk visceral fat (the so-called “middle-aged spread” commonly associated with metabolic syndrome in men) toward the pectoral and gluteofemoral regions, equivalent to female lipid distribution. The intended therapeutic outcome is a measurable reduction in male cardiovascular risk to parity with female baselines.

A double-blind, placebo-controlled study enrolled 84 participants (42 male, 42 female), aged 45–85, with a mean BMI of 34.1. Participants received 3.5 mg FMZ-01 via weekly 5" rectal suppository.

Results Overview

Male Cohort

Outcomes in the male cohort were striking. Visceral fat reduction averaged 68%, accompanied by sharply reduced triglycerides and improved insulin sensitivity, with remaining fatty tissue consolidating as healthy pectoral and gluteofemoral deposits, producing supple subcutaneous fat. Histological analysis confirmed extreme overexpression of aromatase enzymes within these tissues, resulting in the sequestration and conversion of free circulating testosterone to estradiol, an hormonal shift that produced notable improvements in skin elasticity, hair retention, and vascular tone, alongside a measurable decline in prostate-specific antigen (PSA) levels.

Cardiovascular performance across all test subjects improved to that of individuals approximately half their age. The reduction in free testosterone corresponded with a decline in male-specific comorbidities such as prostate hypertrophy, androgenic alopecia, and metabolic fatigue. Side effects included vomiting, muscle weakness, and deviations in libido, though it remains unclear whether these effects stem directly from Fauzempic or indirectly from altered fitness levels.

Economic modelling suggests that nationwide distribution of Fauzempic among middle-aged males could reduce the obesity-related and age-linked burden on the National Health Service by as much as 36%, equating to an estimated £89 billion annual saving when potential secondary behavioural benefits are considered, through the reduction in male-centric incidences of aggression, reckless driving, and occupational injury.

Even participants in their eighties demonstrated fitness that could see them reintegrated as economically productive members of the workforce. A regimen of Fauzempic is projected to cost the NHS approximately £800 per patient per month but could deliver a fourfold return to the national economy.

Female Cohort

The female cohort stood in marked contrast. While improvements in cardiovascular health markers were noted, FMZ-01 induced aberrations in testosterone production and muscular hypertrophy. These two processes, feeding back upon each other, resulted in rampant hirsutism, thickening of the limbs, skull, and vocal cords, and the production of a pungent masculine musk.